Results 201 to 210 of about 111,189 (247)

Unmet needs in the care of patients with neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody associated disease: insights from Germany. [PDF]

Neurol Res Pract
Giglhuber K, Bertrand A, Zappe C, Kleiter I, Ayzenberg I, Berthele A, Neuromyelitis Optica Study Group (NEMOS).   +6 more
europepmc   +1 more source

A 14-Year-Old Male With Susac Syndrome: A Case Report. [PDF]

Case Rep Neurol Med
Kojak MJ, Sleiay M, Sleiay B, Dokhan A, Hamzeh G, Alsmoudi H, Alghadi BM.   +6 more
europepmc   +1 more source

Rituximab combined with lenalidomide for the treatment of marginal zone lymphoma with IgM kappa positivity and cold agglutinin syndrome: a case report. [PDF]

Front Immunol
Zhang X, Zheng Y, Cai S.
europepmc   +1 more source

A Rare Presentation of Mixed Warm and Cold Autoimmune Hemolytic Anemia. [PDF]

Case Rep Hematol
Anya O, Idenyi O, Chikere O, Shatzel JJ.
europepmc   +1 more source

Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study

British Journal of Haematology, EarlyView.
Michael Wang, Wojciech Jurczak, Marek Trneny, David Belada, Tomasz Wrobel, Nilanjan Ghosh, Mary‐Margaret Keating, Tom van Meerten, Ruben Fernandez Alvarez, Gottfried von Keudell, Catherine Thieblemont, Frederic Peyrade, Marc Andre, Marc Hoffmann, Edith Szafer‐Glusman, Jennifer Lin, James P. Dean, Jutta K. Neuenburg, Constantine S. Tam   +18 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Rituximab

Drugs of Today, 2005
Rituximab is a chimeric monoclonal antibody that targets the CD20 molecule on the B-cell surface. It is the first antibody of its kind to be licensed for the treatment of non-Hodgkin's lymphoma. Rituximab was found to be effective, well-tolerated and has a good safety profile, though its precise cellular effects are still not well understood. Rituximab
Tanya, Doan, Elena, Massarotti
openaire   +2 more sources

Rituximab

Zeitschrift für Rheumatologie, 2010
Rituximab as a monoclonal antibody against CD20 was approved for treatment of patients with rheumatoid arthritis (RA) with inadequate response to or contraindication for the use of a TNF blocker. This article focuses on current results from clinical trials at different developmental stages as well as from registry data in anti-TNF non-responders ...
E, Feist, T, Dörner
openaire   +2 more sources

Rituximab

Drugs, 1999
Rituximab is a chimaeric monoclonal antibody which specifically binds to the CD20 antigen on normal and malignant B lymphocytes. It produces antibody-dependent cell- and complement-mediated cytotoxicity in these cells. Rituximab reduced peripheral B lymphocyte counts by approximately 90% within 3 days in patients with relapsed indolent lymphoma. Counts
S V, Onrust, H M, Lamb, J A, Balfour
openaire   +2 more sources

Rituximab in Pemphigus

Immunotherapy, 2017
Pemphigus is a severe autoimmune blistering disease mediated by pathogenic anti-desmoglein antibodies leading to an inter keratinocyte disjunction. Rituximab is a monoclonal antibody that binds to the CD-20 antigen of B lymphocytes, which causes B-cell depletion and a subsequent reduction in pathogenic autoantibodies.
Hebert, Vivien, Joly, Pascal
openaire   +2 more sources